Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabazitaxel - Sanofi

Next Previous
X
Search
Drug Profile

Cabazitaxel - Sanofi

Alternative Names: 116 258; Jevtana; RPR 116258; RPR-116258A; Taxoid XRP6258; Taxoid-116258; TXD 258; XRP-6258

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer AIO Studien gGmbH; Bristol Haematology and Oncology Centre; European Organisation for Research and Treatment of Cancer; German Breast Group; Sanofi; SCRI Development Innovations; Sidney Kimmel Cancer Center; University Hospitals Bristol NHS Foundation Trust
  • Class Amines; Antineoplastics; Benzene derivatives; Esters; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Brain metastases; Breast cancer; Germ cell cancer; Liposarcoma; Penile cancer; Small cell lung cancer
  • Phase I/II Solid tumours
  • No development reported Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Urogenital cancer

Most Recent Events

  • 13 Oct 2023 The Memorial Sloan-Kettering Cancer Center & Sanofi completes a phase II trial for Prostate cancer (Metastatic disease, Combination therapy) in USA (NCT02218606)
  • 01 Aug 2022 The district court dismisses infringement claim related to the 592 patent filed against generic filers by Sanofi in
  • 28 Jul 2022 Sanofi has four Orange Book listed patents protection for Cabazitaxel in US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top